When examining PS exposure, we again observed hyposensitivity to PGI2 inhibition in the type 1 diabetes group compared with control participants when platelets were stimulated with CRP-XL or a combination of SFLLRN/CRP-XL, which was only observed with the higher concentration of the inhibitor (Fig. 3i). Here, CRP is linked to type 1 diabetes mellitus.